|1.||Karlsson, Anna: 2 articles (08/2005 - 10/2003)|
|2.||Johansson, Magnus: 2 articles (08/2005 - 10/2003)|
|3.||Ghavami, S: 1 article (10/2005)|
|4.||Karami-Tehrani, F: 1 article (10/2005)|
|5.||Maddika, S: 1 article (10/2005)|
|6.||Los, M: 1 article (10/2005)|
|7.||Hashemi, M: 1 article (10/2005)|
|8.||Balzarini, Jan: 1 article (08/2005)|
|9.||Bertoli, Ada: 1 article (08/2005)|
|10.||Franco, Maribel: 1 article (08/2005)|
08/01/2005 - "The multisubstrate nucleoside kinase of Drosophila melanogaster (Dm-dNK) can be expressed in human solid tumor cells and its unique enzymatic properties makes this enzyme a suicide gene candidate. "
10/12/2001 - "The efficiency of nucleoside kinase suicide gene therapy for cancer is highly dependent on "bystander" cell killing, i.e., the transfer of cytotoxic phosphorylated nucleoside analogs to cells adjacent to those expressing the suicide enzyme. "
01/01/1986 - "[Effect of hematoporphyrin derivative (HpD) on nucleoside transport and nucleoside kinase activity of cancer cells]."
08/20/1999 - "The cDNA cloning and characterization of Dm-dNK will be the basis for studies on the use of this multisubstrate nucleoside kinase as a suicide gene in combined gene/chemotherapy of cancer."
08/01/1981 - "The activities of deoxycytidine monophosphate deaminase and all the nucleoside kinase were high not only in tumor cells, but also in rapidly growing normal tissues, so that these enzymes are unsuitable as targets for cancer chemotherapy. "
03/01/2004 - "The cytarabine phosphoramidate prodrug 1 has been synthesized and evaluated in comparison with cytarabine for growth inhibitory activity against wild-type, nucleoside transport-deficient, and nucleoside kinase-deficient CEM leukemia cell lines. "
07/01/2001 - "The agents inhibited Tmolt4 leukemia DNA and RVA syntheses after 60 min at 100 microM Multiple enzymes involved with nucleic acid metabolism appeared to be targeted including inhibition of RNA polymerases, ribonucleotide reductase and nucleoside kinase activities, however, inhibition of de novo purine synthesis at the key regulatory enzyme IMP dehydrogenase appeared to be the primary target. "
09/01/1999 - "A mode of action study in Tmolt4 leukemia cells demonstrated that the agents inhibited de novo purine synthesis at the regulatory sites PRPP-amido transferase, IMP dehydrogenase as well as dihydrofolate reductase resulting in significant inhibition of DNA synthesis in 60 min. Other biochemical sites which were affected significantly were thymidylate synthetase, DNA polymerase alpha, RNA polymerases, nucleoside kinase and ribonucleoside reductase."
|3.||Breast Neoplasms (Breast Cancer)
10/01/2005 - "The results of the study, thus, suggest that extracellular adenosine and deoxyadenosine induce apoptosis in both oestrogen receptor-positive (MCF-7) and also oestrogen receptor-negative (MDA-MB468) human breast cancer cells by its uptake into the cells and conversion to AMP (dAMP) followed by activation of nucleoside kinase, and finally by the activation of the mitochondrial/intrinsic apoptotic pathway."
|4.||Osteosarcoma (Osteogenic Sarcoma)
01/01/1994 - "Use of nucleoside kinase-deficient mouse leukemia L1210 cell lines to determine metabolic routes of activation of antitumor nucleoside analogs."
01/01/1994 - "Mouse leukemia L1210 cell lines that were selected for resistance to deoxyguanosine (dGuo-R) or lacked adenosine kinase activity (ED2) were used to evaluate the nature of the nucleoside kinase that was required to phosphorylate nucleoside analogs to their respective active nucleotide form. "
|1.||DNA-Directed RNA Polymerases (RNA Polymerase)
|3.||DNA (Deoxyribonucleic Acid)
|5.||Complementary DNA (cDNA)
|8.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|10.||DNA Polymerase I (Klenow Fragment)
|1.||Drug Therapy (Chemotherapy)